Small molecule · developed by Harmony Biosciences Management
HBS-301 is a delayed-release formulation of pitolisant.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07675135 | Phase 3 | EDS | Recruiting | HRMY |
| NCT07500090 | Phase 3 | Idiopathic Hypersomnia | Recruiting | HRMY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CataplexyEDSFatigueIdiopathic HypersomniaNarcolepsy
See HRMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HRMY catalysts and pipeline →